These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 22245431)

  • 21. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
    Gamas P; Marchetti S; Puissant A; Grosso S; Jacquel A; Colosetti P; Pasquet JM; Mahon FX; Cassuto JP; Auberger P
    Leukemia; 2009 Aug; 23(8):1500-6. PubMed ID: 19340007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Inhibitory effect of 4-chlorobenzoyl berbamine on imatinib-resistant K562 cells in vitro and in vivo].
    Zhang YF; Xu GB; Gan YC; Xu XH; Xu RZ
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Dec; 31(12):1997-2001. PubMed ID: 22200699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
    Kindler T; Breitenbuecher F; Kasper S; Stevens T; Carius B; Gschaidmeier H; Huber C; Fischer T
    Leukemia; 2003 Jun; 17(6):999-1009. PubMed ID: 12764361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
    Xu R; Dong Q; Yu Y; Zhao X; Gan X; Wu D; Lu Q; Xu X; Yu XF
    Leuk Res; 2006 Jan; 30(1):17-23. PubMed ID: 16023722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA; Greene LM; Greene TF; Campiani G; Butini S; Brindisi M; Lawler M; Meegan MJ; Williams DC; Zisterer DM
    Biochem Pharmacol; 2009 Feb; 77(3):310-21. PubMed ID: 19014913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
    Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
    Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
    Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
    Tabrizi R; Mahon FX; Cony Makhoul P; Lagarde V; Lacombe F; Berthaud P; Melo JV; Reiffers J; Belloc F
    Leukemia; 2002 Jun; 16(6):1154-9. PubMed ID: 12040447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
    Czechowska A; Poplawski T; Drzewoski J; Blasiak J
    Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S; Bagchi J; Mandal L; Paul K; Ganguly D; Bhattacharjee S; Ghosh M; Biswas N; Chaudhuri U; Bandyopadhyay S
    Apoptosis; 2009 Mar; 14(3):298-308. PubMed ID: 19153832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
    Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
    Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
    Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
    Mc Gee MM; Campiani G; Ramunno A; Fattorusso C; Nacci V; Lawler M; Williams DC; Zisterer DM
    J Pharmacol Exp Ther; 2001 Jan; 296(1):31-40. PubMed ID: 11123359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ; Pradelli LA; Paul A; Bénéteau M; Jacquel A; Auberger P; Ricci JE
    Cancer Res; 2009 Apr; 69(7):3013-20. PubMed ID: 19318579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.